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Background: Glycogenosis type II (GSDII or Pompe disease) is an autosomal recessive disease, often characterized
by a progressive accumulation of glycogen within lysosomes caused by a deficiency of α-1,4-glucosidase (GAA; acid
maltase), a key enzyme of the glycogen degradation pathway. To date, more than 326 different mutations in the
GAA gene have been identified in patients with GSDII but the course of the disease is difficult to be predicted on
the basis of molecular genetic changes. Studies on large informative families are advisable to better define how
genetics and non genetics factors like exercise and diet may influence the clinical phenotype.
Methods and results: In this study, we report on clinical, instrumental, and pathological features as well as on
molecular analysis of a family with 10 out of 13 siblings affected by late-onset Pompe disease. Three mutations
segregated in the family, two of which are novel mutations. Siblings showing a more severe phenotype were
compound heterozygous for c.118C > T [p.R40X] and c.2647-7G > A [p.N882fs] on GAA, whereas, two patients
showing a mild phenotype were compound heterozygous c.2647-7G > A [p.N882fs] and c.2276G > C [p.G759A]
mutations. Quantitative expression analysis showed, in the patients carrying p.R40X/ p.N882fs, a significant (p 0.01)
correlation between the levels of expression of the mutated allele and the age at onset of the disease.
Conclusions: As far as we know, this is the largest informative family with late-onset Pompe disease described in
the literature showing a peculiar complex set of mutations of GAA gene that may partially elucidate the clinical
heterogeneity of this family.
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Glycogenosis type II (GSDII, or Pompe disease; MIM
232300) is an autosomal recessive storage disorder due
to mutations of the acid α-glucosidase gene (GAA) on the
chromosome 17q21-23 which causes absent or deficient
activity of the lysosomal enzyme acid α-glucosidase
(GAA) [1]. GAA catalyzes the hydrolysis of α-1,4 and α-1
,6 links of glycogen into the lysosomes; its activity reduc-
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reproduction in any medium, provided the orcontrol levels, leads to a progressive accumulation of
glycogen within these organelles, and, later, between myo-
fibrils. GAA is ubiquitous in the body, but its shortening
is particularly harmful in muscle tissues, and contributes
to determine the clinical phenotype by cardiac, skeletal,
and respiratory muscles involvement [1,2].
GSDII is clinically classified into classic infantile and
late-onset forms. The classic infantile form is character-
ized by marked generalized muscle weakness and severe
cardiomyopathy with rapid progression and a fatal out-
come within the second year of life. Late-onset form
comprises a wide spectrum of highly variable phenotypes
which are dominated by limb-girdle, paraspinal, and
respiratory muscles weakness [2].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ferent mutations of the GAA gene including missense,
nonsense, large and small insertions and deletions, as
well as frame-shift and splicing changes, as listed in the
latest update (25 June 2012) of the Erasmus Mutation
Database. All these mutations occur in homozygous or
compound heterozygous affected individuals and are as-
sociated with absence of GAA activity in the infantile
form, and with a residual GAA activity ranging 3-35% of
control values in the late onset forms. These data indi-
cate a clear cut relationship between enzyme activity
levels and severity of phenotype in the infantile form
whereas, in late-onset patients, there is no definite cor-
relation [3-9]. These evidences lead to hypothesize that
the expression of GAA mutations could be modified by
genetic background and non genetic factors (life-style,
nutrition, and environment) [10,11]. Studies on inform-
ative families, where GAA-mutated members have the
closest possible genetic background are advisable to bet-
ter define the genotype-phenotype correlation. This
could be particularly useful in families with a late-onset
form in order to detect other relatives initially affected
that could be early treated by Enzyme Replacemement
Therapy (ERT), approved since 2006 either for children
or for late onset form with effective results [12]. We re-
port herein the detailed clinical, pathological, and mo-




A 41-years-old man (II-7) was admitted to our Depart-
ment complaining of progressive difficulties in walking,
back pain, and easy fatigability since 3 years. His older
brother II-2 was confined to the wheelchair since 6 years
because of an undefined myopathy, while 11 other sib-
lings were reported to be healthy. His father had died
because of respiratory failure and his mother for myo-
cardial infarction, at 69 and 71 years of age, respectively.
Patient neurological examination showed waddling gait
and hyperlordosis resulting from paravertebral and
pelvic-girdle muscles weakness. Serum CK, LDH, ALT,
and AST values were, respectively, 466, 180, 65, and 58
U/L, respectively. EMG revealed a myopathic pattern.
Echocardiography disclosed aortic arch dilation.
Right vastus lateralis muscle biopsy was performed
and muscle specimens processed with standard proto-
cols for histological, hystochemical, and ultrustructural
studies. These showing scattered intracytoplasmic vac-
uoles with basophilic amorphous materials inside, in
addition to mild fiber size variation as well ultrastruc-
tural studies detecting a widespread fiber vacuolation
with glycogen accumulation within lysosomes, sug-
gested a diagnosis of GSDII disease (Figure 1) whichwas confirmed by GAA activity assay on muscle hom-
ogenate [13,14].
Family studies
The pedigree of this family (Figure 2) includes 13 sib-
lings (9 males and 4 females) in the second generation
born from non-consanguineous parents. Clinical data on
the grandparents’ families and relatives were not avail-
able. The numerous descendants (36 individuals; age
ranging 6–32 years) are reported to be healthy but we
have not yet examined them all. Few weeks after the
evaluation of the index case, his brother confined to a
wheelchair (II-2) died suddenly of respiratory failure at
54 years of age. After this sad event, all of them decided
to be clinically visited in our Department. To determine
as precisely as possible their age at first symptoms onset,
the period during which they started to experience im-
pairment of motor functions in daily activity was asked.
Informed consent was obtained from each patient. The
study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki, as reflected in the a
priori approval by the institution's human research
committee.
Clinical examination
10 out 11 siblings were screened collecting their clin-
ical history and neurological examination. Skeletal
muscle strength was evaluated by manual muscle
testing (MMT) using the Medical Research Council
(MRC) grading scale (range 0–5). Tongue strength was
also assessed using the manual method described by
Dubrovsky et al. [15].
Muscle functions were assessed using the Gait, Stairs,
Gowers, Chair (GSGC) scale [16]. Functional endurance
during prolonged ambulation was evaluated with the
six-min walk test (6MWT).
Respiratory function was evaluated measuring forced
vital capacity (FVC) with spirometry in the upright and
supine positions [17,18]. Results were expressed as a
percentage of predicted normal values. Values lower
than 80% of predicted indicating variable degrees of
restrictive respiratory disease, ranged from mild to
very severe, according to American Thoracic Society
standards [19].
Cardiac function was evaluated by clinical examin-
ation, baseline EKG and echocardiography.
Routine blood analyses were performed including CK,
LDH, AST, and ALT, calcium, phosphorus, and magne-
sium levels as well as thyroid hormones concentrations
and thyroid antibodies titers assessment.
Electrophysiological study
Concentric needle EMG was performed. Spontaneous
activity was assessed at rest during insertion and
Figure 1 Cryostatic sections of vastus lateralis muscle biopsies. A) HE, with muscle fibres showing vacuoles of variable size, the vast majority
of which contain PAS (B) and acid phosphatase (C) positive material. The muscle biopsy of the sibling II-8 disclosed peculiar microscopic changes
consisting in thin gaps surrounding paracentral nuclei (D, Gomori, arrows) at level of which PAS (E, asterisk) and to a lesser extent acid
phosphate (F, arrowhead) positive deposits were seen in some fibres. (Upper series 10×; lower series 20×).
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tivity pattern at maximal voluntary contraction were
evaluated. The left deltoid, the right tibialis anterior
and the abductor digiti minimi as well as paraspinal
lumbar and dorsal muscles were studied.Figure 2 The complete pedigree of the Pompe Italian family.Muscle histology and biochemistry
Open biopsy of the vastus lateralis of the right quadri-
ceps muscle was performed, after informed consent, in 7
affected individuals (II-4, 5, 7, 8, 9, 12, 13) apart from II-
1 and II-6 who refused the biopsy. Three muscle
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to standard procedures for histology and biochemistry
studies and for the extraction of nucleic acids.
Measurement of GAA activity
The GAA activity was determined on dried blood spots,
in all siblings participating to the study, using both
tandem mass spectrometry and fluorimetry [20,21].
Muscle residual GAA activity was also measured on
homogenate of frozen muscle specimens in 7 affected
siblings (II-4, 5, 7, 8, 9, 12, 13), according to the methods
above mentioned [13,14].
Muscle imaging
Whole Body Muscle Magnetic Resonance Imaging (WB-
M-MRI) was performed on a 1.5-Tesla (40 mT/min,
max. - slew rate 200 T/m/s) whole-body scanner
(Magnetom Avanto, Siemens Medical System, Erlangen,
Germany) using GRAPPA algorithm as integrated Paral-
lel Acquisition Technique (iPAT) to minimize acquisi-
tion time [22-24]. The scanner allows the connection of
up to 76 receiver elements from multiple phased-array
surface coils, covering the patient from head to toe, with
simultaneous signal reception from 32 independent re-
ceiver channels. In the scanner, the patient was placed in
the supine position with arms along the body and exam-
ined from head to ankles with T1 and T2 sequences at
five body levels in the coronary orientation: head/neck,
pelvis, thighs and ankles as well as the thorax/abdomen;
Imaging parameters were TR/TE 577/11, 5 mm slices,
384 × 384 for T1 acquisition and TR/TE 5720/87, 5,00
mm slices, matrix 384 × 384 for T2 acquisition; pro-
spective two-dimensional (2D) navigator correction of
the respiratory phase (PACE, prospective acquisition
correction) to avoid breath artifacts. Using PAT acceler-
ation, whole-body STIR imaging was possible within
12:28 min and T1-weighted imaging within 16:10 min at
a 1.3 × 1.1 mm and 1.8 × 1.3 mm in-plane resolution,
respectively. For the coronal whole-body imaging a PAT-
factor of 3 was used, except from the ankles that were
acquired with a PAT factor of 2. After the examination,
the images were electronically aligned to one image of
the whole body in the coronal plane. Including localizer
time, total acquisition time for WB-MRI was 45 min,
mean room time was 54 min. The total imaging time
was about 30 minutes. Before the examination, patient
was requested to restrain from excessive ambulation or
exercise because T2 sequences potentially being affected
by exercise or activity [25].
Intracranial arteries study
Magnetic Resonance Angiography (MRA) was performed
by Angio-RM TOF 3D axial Siemens Synphony 1.5 T to
evaluated intracranial arteries for vessel wall ectasia and/oraneurysm. Vessel total square diameter was measured at
the apex and middle third of the basilar artery and at the
middle third of the intracranial portion of right and left in-
ternal carotid artery.
Bone mineral density (BMD)
Total body, lumbar, and femur scans were obtained by
Dual x-ray absorptiometry (DXA model DPX-L, LUNAR
Radiation, Madison, WI, USA). Acquired data were ana-
lyzed using the LUNAR Radiation body composition
program to determine BMD for total body, arms, legs,
and trunk. According to the World Health Organization
standards results were scored as follows: BMD z score
greater than − 1, between − 1 and − 2.5 and less than −
2.5 corresponding to normal, osteopenia, and osteopor-
osis, respectively [26].
Mutation analysis
Genomic DNA was isolated from blood lymphocytes of
the patients, according to standard procedures. DNA
was quantified and diluted at 20 ng/μL for the amplifica-
tion by PCR.
The GAA gene (NG_009822.1) was amplified by PCR
from genomic DNA. All exons and flanking intron se-
quences were amplified using specific primer pairs avail-
able on request. In a final volume of 25 μl, 100 ng of
genomic DNA was combined with 0.5 μM of each pri-
mer, 0.2 mM all dNTPs, 1× buffer (20 mM Tris, 10 mM
Hepes, 2.5 mM magnesium sulfate, 10 mM potassium
chloride and 10 mM ammonium sulfate) (Fermentas)
and 1U of Dream Taq (Fermentas). After polymerase ac-
tivation for 3 min at 94°C, reactions were carried out for
30 sec. at 94°C, 30 sec. at melting temperature and 45
sec. at 72°C for 40 cycles and 8 min at 72°C for finally
extension. PCR products were confirmed by electrophor-
esis in 1.5% agarose gel and sequenced [27].
Sequencing
PCR products where directly sequenced on both strands
using the Big Dye Terminator Ready Reaction Kit (Ap-
plied Biosystems). Sequencing reactions were performed
on a 9700 Thermal Cycler (Applied Biosystems) for 25
cycles of 95°C for 10 sec., TM for 5 sec. and 60°C for 2
min. After the sequencing, each reaction was column-
purified (Amersham) to remove excess dye terminators,
and was subsequently run on the ABI prism 3700 Genetic
Analyser (Applied Biosystems). Sequences were analyzed
using multiple alignments of sequences with the program
Autoassembler (Applied Biosystems) [28].
mRNA extraction and cDNA sequencing
RNAs were isolated from muscle biopsies using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions, and dissolved in diethyl
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extracted by skeletal muscle biopsies of seven siblings
(II-4, 5, 7, 8, 9, 12, 13) and two control muscles from the
Neuromuscular Tissues Bank of the Second University
of Naples, was reverse transcribed with the Transcriptor
HiFi cDNA Synthesis kit (Roche). For the amplification
of the cDNA fragment comprising the alternative splice
site, was used a forward primer designed in exon 18
combined with a reverse primer in exon 20 (forward:
CACCATCAACGTCCACCTCC and reverse: GTGT
CGGGGCTGTAGGTGAA). PCR amplification was
performed in a final volume of 25 μl using 20 ng of
single stranded cDNA, as described before.
Expression analysis of the mutated c.2647-7G > A transcript
To examine the expression pattern of the alternative
transcript generated by the c.2647-7G > A mutation
qPCR assay was performed using a specific oligonucleo-
tide designed to detect only the alternative transcript.
qPCRs were performed using 10 ng of cDNA, 0.5 μM of
human GAA transcript-specific primers and 1× of
FastStart Universal SYBR green Master Mix (Roche) in a
total volume of 20 μl. Thermal cycling was performed
using the LightCycler System DNA Engine Opticon 2
(MJ Research) with an initial denaturation of 10 min. at
95°C, followed by 40 cycles of 15 sec. at 95°C, 60 sec.
at 60°C. Each reaction was performed in triplicate and
PCR products were analyzed by electrophoresis on 3%
agarose gels. The expressions were normalized versus
‘glyceraldehyde 3-phosphate dehydrogenase (GAPDH)’
to account for differences in starting material and cDNA
reaction efficiency [28].
GAA transcript primers were forward primer 5′
TTCCTGGCCAGGAATCCCAG 3′and reverse primer
5′ GTGTCGGGGCTGTAGGTGAA 3′; the GAPDHTable 1 Main demographic and clinical data of GSD II sibling
II-1 II-4 II-5 II-6
Sex M F F M
Age 1 56 50 53 54
Age 2 66 59 57 57
MMT-MRC (%) 94 79 82 97
GSGCA(X/27) 25 12 12 25
6MWT (m) 580 297 225 600
CK 170 404 255 140
FVC % 12,8 35 46 11
DBS 3.95 2.70 0.12 4.1
Muscle GAA 4.2 2.5
Cereb.Anom. + + + +
The ID number of the patients was relative to the pedigree showed in Figure 2. Ag
(%): manual muscle testing (MMT) using the MRC (Medical Research Council) gradin
creatine kinase (50–190 U/L); FVC %: forced vital capacity (drop from sitting to supin
tissues (34 – 138 pmol/min/mg protein); CA: Angio MR cerebral anomalies.
With + is indicated the presence of anomalies; with - is indicated the absence of anprimers were forward primer 5′AGCCACATCGCTC
AGACAC 3′ and reverse primer 5′GATCTCGCTCC
TGGAAGATG 3′.
Results
Clinical evaluation of the affected siblings
Main demographic and clinical data of all affected sib-
lings are summarized in Table 1. The first symptoms for
all affected siblings were fatigability and pain which were
complained at mean age 43,2 ± 11,04 years (range 20–56
years), including in this calculation also the sibling II-2
who was reported to have symptoms since he was about
20 years old. Age at first symptoms was 40,5 ± 13,3 years
in male and 47 ± 6 years in female. The mean time lag
between early symptoms and diagnosis was 7,4 ± 3,7
years in living siblings, while the reported disease dur-
ation was 34 years in the sibling II-2.
The neuromuscular evaluation showed paraspinal
muscles weakness with lumbar hyperlordosis in all af-
fected siblings combined with proximal limb muscle
weakness (moderate to severe in pelvic and slight to
moderate in scapular girdles), waddling gait, winging
scapula and positive Gower’s sign in 7 (II-4, 5, 7, 8, 9,
12, and 13). Tongue and velo-pharyngeal muscles in-
volvement with nasal speech were present in 2 siblings
(II-1 and II-6) who referred occasional swallowing diffi-
culties. The severity of muscle weakness varied between
the siblings regardless of gender and duration of disease.
A significant relationships was calculated, in all af-
fected siblings (II-1, 4, 5, 6, 7, 8, 9, 12, 13), comparing
age at onset with muscle function impairment scored
by GSGC (p < 0.005; R20,8) and with skeletal muscle
strength scored by MMT using the MRC grading scale
(p < 0.006; R20,7). Neuromuscular exam was normal in
sibling II-10.s
II-7 II-8 II-9 II-10 II-12 II-13
M F M M F M
40 47 38 - 39 35
53 51 50 - 44 42
76 86 74 100 78 75
7 9 9 26 8 6
324 325 254 610 268 254
582 565 404 110 353 887
17 18 20 8 21 18
0.11 0.04 0.09 20 0.12 0.31
2.6 2.3 2.4 2.5 3.1
+ ND + - + +
e 1: Age at first symptoms (years); Age 2: Age at diagnosis (years); MMT-MRC
g scale; GSGCA: Gait, Stairs, Gowers, Chair, Arms; MWT: six-min walk test; CK:
e); DBS: GAA activity (1,86-21,9 mol/h/l; Muscle GAA: GAA activity in muscle
omalies; ND: not determinate.
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1.5-4 times the normal values in all patients, apart from
two II-1 and II-6; all other blood parameters were nor-
mal, apart from anti-thyroglobulin and anti-peroxidase
antibodies titers which were elevated (229.2 UI/mL and
3000 UI/mL) in II-8. Cardiac alterations were not found.
FVC in the upright position was ≥80% of the predicted
normal in 4 out of 10 siblings (II-1, 6, 8, 10), thus indi-
cating pulmonary function within normal limits, whereas
the other 6 (II-4, 5, 7, 9, 12, 13) had FVC upright values
ranging 51-79% which dropped in the supine position as
compared to normal values, thus indicating a restrictive
respiratory disease ranging from a mild to a moderately
severe degree, according to the American Thoracic
Society standards [19]. Differences in FVC from upright
to the supine positions varied less than 10%, in siblings
II-6 and II-10, as observed in individuals without re-
strictive respiratory impairment, whereas they ranged
11–26% in the remaining 8 siblings (II-1, 4, 5, 7, 8, 9, 12,
13), thus indicating the presence of varying degrees of dia-
phragmatic weakness. A significant relationships (p < 0.05;
R20,7) was calculated comparing the age at onset and
respiratory function impairment scored by FVC in siblings
II-4, 5, 7, 8, 9, 12, 13.
EMG revealed a myopathic pattern characterized by
reduced amplitude and duration of motor unit potentials
in all muscles explored and pseudomyotonic discharges
registered in paraspinal muscles in 9 siblings (II-1, 4, 5,
6, 7, 8, 9, 12, 13) and in tibialis anterior muscle of 3 of
them who complained of a steppage and waddling gait.
Muscle biopsy showed the typical pattern of a vacuolar
myopathy with intralysosomal glycogen accumulation of
variable severity in 6 (II-4, 5, 7, 9, 12, 13) out of 7 pa-
tients who underwent muscle biopsy. Vacuolated muscle
fibers counted on 3 different histological sections of each
muscle specimen ranged from 10 to 100% of the total,
without correlation with duration of the disease, age,
and gender. Muscle biopsy of II-8 disclosed minor
changes with minimal accumulation of glycogen and
lysosomes surrounding the paracentral nucleus in only
few fibers.
Residual α-glucosidase activity was markedly reduced
on both dried blood spots (0.04 – 4.1 mol/h/l; normal
range 1.86-21.9 mol/h/l) and muscle tissues at values
less than 12% of controls (2.3 - 4,2 pmol/min/mg pro-
tein; normal range 34 – 138 pmol/min/mg protein).
WB-M-MR of skeletal muscle was performed in 8 af-
fected siblings (II-1, 4, 5, 6, 7, 9, 12, 13) while the sibling
II-8 could not be examined carrying a paramagnetic
prosthesis. A mild fatty infiltration and atrophy of ad-
ductor magnus, semimembranous, and semitendinosus,
long head of the biceps femoris, vastus intermedius, and
medialis as well as of the lumbar and at a lower degree
of the dorsal paraspinal muscles were observed in 6siblings (II-4, 5, 7, 8, 12, 13). Muscle involvement was
usually symmetrical with the exception of II-5 who
showed unilateral atrophy of adductor longus of the
thigh. The remaining two patients (II-1, 6) disclosed only
a mild fatty infiltration and thinning of paraspinal mus-
cles as well as tongue atrophy.
At MR Angiography dilation of intracranial internal
carotid was observed in 8 siblings examined (II-1, 4, 5, 6,
7, 9, 12, 13), whereas basilar artery dolichoectasia was
found in 6 (II-4, 5, 7, 9, 12, 13) of them.
DXA examination disclosed osteoporosis in the sibling
II-4, osteopenia in II-5, 8, and 13 and it was normal in
the other affected and not affected siblings.
GAA mutation analysis
In the DNA sample of the index case (II-7) a nonsense mu-
tation (c.118C >T) was identified in exon 2. This mutation,
already described in literature (www.pompecenter.nl), sub-
stitutes an arginine with a stop codon at amino acid 40
(c.118C >T [p.R40X]), and segregates in heterozygous in 7
out of 10 examined siblings (Figure 3A). No further coding
mutations were found in this patient, whereas sequence
analysis revealed a heterozygous variant in the last 7 nucle-
otides of intron 18 (c.2647-7G >A) (Figure 3B).
By means of a splicing prediction program (http://www.
umd.be/HSF/) a 43% probability was calculated that the
c.2647-7G >A change may create a new canonical splicing
site in intron 18. Failure in identifying this change in any-
one of 200 individuals from healthy population as well as
its absence in the dbSNPs (www.ncbi.nlm.nih.gov/projects/
SNP/) and 1000Genome (www.1000genomes.org) data-
bases, suggested this change (c.2647-7G >A) to be a novel
mutation of GAA. This alternative splice-site inducing
change segregated in heterozygous in all 9 examined af-
fected siblings of the family (Table 2). Siblings II-1 and II-6,
only carrying the c.2647-7G >A mutation, were investi-
gated for further changes of the GAA gene. By sequencing
all exons of GAA, a novel change c.2276 G >C in exon 16,
was found in heterozygous in both of them, (Figure 3C).
This change causes a glycine to alanine amino acid substi-
tution at position 759 (c.2276G >C [p.G759A]), it is absent
in 200 samples from healthy population and it is not
reported in the dbSNPs and 1000 Genome databases.
Segregation analysis in the sibship showed that apart from
II-1 and II-6 this novel mutation was present in simple
heterozygous in one further sibling (II-10) only, who is
healthy. Evolutionary conservation analysis showed that the
glycine at position 759 is highly conserved in all species
(Figure 3D), thus supporting a functional role for this
mutation.
Expression analysis of the c.2647-7G > A mutation
Canonical and alternative splicing mRNAs were found in 7
skeletal muscle biopsies from our patients, confirming that
Figure 3 Mutation analysis of GAA gene. A to C Results of sequencing analysis and detection of mutations in exon 2 (c.118C > T [p.R40X]),
intron 18 (c.2647-7G > A [p.N882fs]) and exon 16 (c.2276 G > C [p.G759A]). Arrowheads mark the site of base alternations. The sequences of an
unaffected sample and an affected subject from the Pompe-affected family are reported. The coding triplets and corresponding amino acids
decided according to GAA cDNA are indicated. D Evolutionary conservation of the glycine residue at position 759 was indicated with an arrow.
Table 2 Genotype –phenotype correlation of GSD II siblings
II-1 II-4 II-5 II-6 II-7 II-8 II-9 II-12 II-13
c.118C > T[p.R40X] + + + + + + +
c.2647-7G > A [p.N882fs] + + + + + + + + +
c.2276G > C [p.G759A] + +
ICA dilation + + + + + + + + +
Paraspinal muscle involvement + + + + + + + + +
LG-like + respiratory myopathy + + + + + + +
Dolichoectasia of Basilar artery + + + + + + +
Tongue weakness + +
Nasal speech + +
The ID number of the patients was relative to the pedigree showed in Figure 2: ICA = Internal Carotid Artery; LG = limb-girdle.
With + is indicated the presence of mutations and/or symptoms.
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only the canonical transcript was present in control mRNA
(Figure 4A). The mutated was less than the normallyFigure 4 Expression analysis of the aberrant transcript obtained by th
detection of intron 18 mutation (c.2647-7G > A [p.N882fs]) in RNAs from m
cDNA sequence producing a frame shift. B Schematic representation of the
aberrant transcript. C The histogram shows the normalized expression valu
carrying the c.2647-7G > A [p.N882fs] mutation. D Linear regression analys
disease and the normalized expression value of the aberrant transcript i
pedigree number.spliced transcript in all patients ranging from 20% to 40%
of the total but always at lower level than the normal allele
(Figure 4A). This data confirmed that the c.2647-7G >Ae c.2647-7G > A mutation. A Results of sequencing analysis and
uscle biopsies. The mutation inserted 5 bp of the intron 18 in the
primers (P1 and P2) used in real time experiment to detect only the
e of the aberrant transcript in RNA of muscle biopsies of the patients
is using SPSS 13.00 software between the age of onset of the
n muscle biopsies. The circles were numbered corresponding to the
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The mutated transcript has 5 nucleotides (CCCAG) of the
intron 18 in the RNA sequence producing a frame shift
which causes a premature truncation of the protein
(c.2647-7G >A [p.N882fs]) (Figure 4A and B). Quantitative
mRNA expression assay (qRT-PCR), specific for the
mutated allele, confirmed an inter-individual variable
expression of the mutant transcript (Figure 4B and C).
Linear regression analysis, performed using SPSS 13.00
software, showed a significant correlation (R2 = 0.7; p <
0.01; R2 = 0.6; p < 0.05) between the normalized expres-
sion value level of the mutated transcript in muscle
biopsies, of those patients carrying p.R40X/p.N882fs
mutations, with the age of onset of the disease and with
GSGC score respectively (Figure 4D).
Discussion
The present study was aimed to define as accurately as
possible the phenotype and the complete coding se-
quence of GAA in affected and healthy individuals of a
very large Italian pedigree with adult onset GSDII.
Several genotype/phenotype correlation studies in
GSDII patients have well established that a) GAA re-
sidual activity of less than 3% the normal is highly recur-
rent in the classic infantile form whereas it neither falls
below this threshold nor exceeds 35% of control values
in late-onset patients; b) certain combinations of GAA
mutations invariably cause the classic infantile form and
others the less severe ones [1]; c) GAA mutations modify
the levels of GAA residual activity in a constant and re-
producible way when assessed in vitro, but their expres-
sion is less well predictable in vivo [1]. In late-onset
GSDII patients, indeed, the levels of GAA enzyme activ-
ity and the severity of clinical pictures may be highly
variable between individuals, even in those who harbor
the same combination of GAA mutations [7,29]. To
explicate the lack of a direct correlation between GAA
mutations and clinical phenotypes a role has been hy-
pothesized of different bio-molecular events which co-
operate in translation, folding, transport ,and maturation
of GAA, as well as in regulating the carbohydrates en-
ergy metabolism of the body. This “genetic background”
might modulate the effect of the combinations of GAA
mutations on the disease phenotype together with envir-
onmental agents and individual habits. However, it has
not been possible to verify this hypothesis until now,
due to the lack of large informative families, at least in
series of Caucasian patients.
In the family herein described, both the clinical-
pathological phenotype and the biochemical and mo-
lecular features supported the diagnosis of late onset
GSDII. The molecular analysis showed that 3 different
mutations segregate in the siblings of the second gener-
ation. In 7 out of 10 examined siblings, the diseasephenotype is linked to the mutation p.R40X which gen-
erates a null allele combined with the frameshift muta-
tion p.N882fs which has not been reported previously.
p.R40X has already been described in homozygous in
two infantile patients and in heterozygous in two unrelated
late onset French patients, combined with the common
IVS1-13T > G mutation [29,30]. Two further siblings
(II-1, II-6) disclosed the same novel mutation p.N882fs
but combined with a further novel missense mutation
p.G759A on the other GAA allele. The remaining af-
fected sibling (II-2) had died at the time of our observa-
tion and neither clinical examination nor genotyping were
possible. This patient differs from all other siblings mainly
for earlier disease onset. Indeed, his siblings reported he
was taken to medical observation for muscle problems
first at the age of 20. We have neither explanation for the
early disease onset nor we know the exact cause of his
death. Indeed, he was followed up by an expert team of
physicians for several years and he was considered not to
need mechanically assisted ventilation. Therefore a cause
for his sudden death different from Pompe disease cannot
be excluded with certainty.
The p.G759A mutation was also found in simple het-
erozygous in one healthy sibling (II-10).
Taking into account the different disease phenotypes
which we have observed in our sibship a marked
inter-individual clinical heterogeneity seems to emerge.
However, the genotype-phenotype correlation allows to
associate specific disease features to different mutation
compound in siblings. In fact, internal carotid artery dila-
tion and paraspinal muscles involvement were present in
all affected siblings who all share the p.N882fs mutation.
These features were selectively associated with either basilar
artery dolichoectasia and involvement of limb-girdle and
respiratory muscles, or with tongue weakness and nasal
speech, in those siblings who harbored the combination
of p.R40X/p.N882fs and p.N882fs/p.G759A mutations,
respectively (Table 2).
Cerebrovascular anomalies have been quite frequently
described in recent studies on both sporadic and familiar
cases of late-onset GSDII, however they do not seem to
occur in all patients [31]. Our data and those of the
literature support the hypothesis that cerebral-vascular
anomalies in late-onset GSDII patients may be related
to specific combination of GAA mutations, however
further studies on large series are advisable.
The pattern of distribution of the disease phenotypes
in our family suggests that in GSDII patients with a
common genetic background the effects of the combin-
ation of GAA mutations may prevail on demographic
factors and individual habits. These latter, however, to-
gether with the selective vulnerability of the affected tis-
sues to the derangement of GAA dependent glycogen
metabolism, likely modulate the severity of the disease
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factors in modifying the disease phenotype is suggested
by the findings in the sibling II-8, who assumes
levotyroxine from several years due to autoimmune-
thyroiditis induced hypotyroidsm. Results of clinical,
muscle biopsy and GAA mutation expression studies
disclosed definite differences with respect to the mea-
surements performed in her siblings who harbor the
same combination of GAA mutations.
The importance of thyroid hormones as regulators of
skeletal muscle metabolism and gene expression is well
known and their likely role as genotype/phenotype modify-
ing factors in GSDII deserves to be evaluated [32,33].
The novel missense mutation p.G759A is a mild vari-
ant which combined with the N882fs splicing mutation
contributes to determine a peculiar mild disease pheno-
type, in two siblings. Most interestingly, we have found
this p.G759A mutation together with a null allele muta-
tion in an unrelated late-onset GSDII patient who shows
involvement of oral and pharyngeal muscles associated
with a moderate degree of weakness of limb girdle and
respiratory muscles (data not published).
Age at onset of the disease, distribution, and degree of
muscles involvement and rate of progression of the clin-
ical picture varied strikingly between the affected mem-
bers of our family who carried the p.R40X/p.N882fs
mutation. Studying muscle changes on H&E stained sec-
tions did not allow us to find any relationship between
degree of muscle vacuolation and age, gender and dur-
ation of the disease. Conversely, preliminary quantitative
expression studies on these siblings show that this
phenotype heterogeneity may be partially explained
by inter-individual variable expression of the mutant
p.N882fs transcript.
The most relevant finding in our study is the occur-
rence of three mutations, two of which being previously
unreported, distributed in a very large sib-ship, which
represents an informative cohort to follow the pheno-
type effects of different mutational complexes in pres-
ence of reduced inter-individual differences in the
genetic-background. The pattern of transmission of p.
R40X and p.G759A mutations strongly suggest they
were both carried by one parent, likely the father,
reported to have died for respiratory failure at 69 years
of age. The occurrence of 3 different mutations in the
first generation of our pedigree could explain the very
high incidence of affected individuals in the same sib-
ship, which gives the wrong suggestion of a dominant
transmission. Similarly 3 different mutations of GAA in
non-consanguineous parents have already been reported
in a pedigree in which the father carrying 2 mild muta-
tions (p.Asp404Asn and c.-32-13T > G) did not have any
outward manifestation of late onset Pompe disease and
the healthy mother carried the p.Leu811fs mutationalone [34]. They were genetically investigated only after
the birth of their first child who showed the classic in-
fantile Pompe disease. Furthermore, patients have been
published, showing a mild late-onset disease phenotype,
in whom only one mutation has been identified [35,36].
These cases may be explained by the presence of a null
allele and/or a regulative mutation or by lacking sequen-
cing of all GAA exons.
Conclusion
This work report the largest informative family with
late-onset Pompe disease described in the literature
showing a peculiar complex set of mutations of GAA
gene that partially elucidate the clinical heterogeneity of
this family.
Nowadays, a complete molecular analysis of the GAA
gene of affected individuals is highly recommended
either for a better understanding of the genotype-
phenotype relationships or, more importantly, to have
the opportunity to be prepared to administer future
selective therapies based on the specificity of GAA
mutations.
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